Background
==========

The world population is ageing; in 2000 there were 600 million people aged 60 or over, and it is estimated that this figure will double by 2025, and more than triple to 2 billion by 2050 \[[@B1]\]. Between 2007 and 2027 the number of people aged 65 years or older in England alone is predicted to increase by 200,000 each year, rising from eight to 12 million over that 20-year period \[[@B2]\]. In the USA numbers aged 65 years or older are predicted to rise from 37 million in 2006 to 63 million by 2025 \[[@B3]\].

The \"oldest old\", often defined as those aged 85 or older, show the largest increase in numbers. By 2066 it is anticipated that there will be almost a third of a million people aged 100 years or older, in a population of 70 million in the UK \[[@B2]\]. In the USA the prediction is for a third of a million over the age of 100 years by 2020 \[[@B3]\].

This demographic change has obvious implications for individuals and society. It will impact particularly on healthcare provision, especially as longer life does not necessarily mean more years enjoyed in good health. It becomes increasingly important to highlight common medical problems in older people, especially if their extent and potential significance are not generally recognised. We suspected that anaemia might be one such problem.

Anaemia is often defined in terms of the WHO criteria, established in 1968 \[[@B4]\]. The WHO definition of anaemia is a haemoglobin (Hb) concentration \<130 g/L in men, and \<120 g/L in women. There has been debate about the use of these values \[[@B5]\], and in particular, whether they should be used to define anaemia in older people \[[@B6]\], but there is no widely accepted alternative definition of anaemia in this age group.

In general, haemoglobin levels are lower in older than in younger people. The reasons for this are not completely understood. It is unclear whether haemoglobin falls in older people because this is a feature of normal ageing, or whether it is always pathological, even if underlying conditions cannot be identified. In an individual patient it may be that some decline in haemoglobin occurs as part of normal ageing, but that disease may also contribute to the development of anaemia.

Anaemia of chronic disease, or anaemia of chronic inflammation, is the term associated with some chronic medical conditions, such as chronic renal disease and rheumatoid arthritis. Older people who suffer such chronic conditions might be expected to be anaemic, just as younger patients are. However, it is not always appreciated that older patients who suffer other medical problems, for example cognitive impairment, have a worse prognosis if they are also anaemic. It is not surprising that anaemia is associated with heart failure or myocardial infarction or death, but the reasons underlying the association between anaemia and other morbidity are less tangible.

We report on the prevalence of anaemia in cohorts of older people in the general population.

Methods
=======

MEDLINE and EMBASE (Ovid interface) were searched for the years 1980 to February 2007 for studies reporting prevalence of anaemia in elderly populations or cohorts, using search strategies described in Additional file [1](#S1){ref-type="supplementary-material"}. It is known that observational studies can be difficult to identify through electronic searching \[[@B7],[@B8]\], so reference lists of retrieved studies and reviews were also searched carefully for further reports, together with \"linked articles\" in PubMed. Full reports were obtained whenever possible for all studies identified from their abstracts as potentially useful.

Studies were included if they reported prevalence of anaemia for cohorts of at least 100 individuals aged predominantly 65 and over living in developed countries, together with the criteria used to define anaemia. Studies of anaemia prevalence in specific disease groups (diabetes, rheumatoid arthritis, renal disease) or in \"extreme\" populations (extreme poverty, poor nutrition) were excluded. Where more than one paper reported on the same or overlapping cohorts, or subgroups of large cohorts, care was taken to avoid double counting, and the report with the most information on the largest number of individuals was used. We limited the search to studies published since 1980 to avoid possible historical changes in prevalence, which might be due to improvements in diet and general health.

For each report we extracted information on the country of residence, how the cohort was selected (for instance, random sampling, inclusive cohort) and whether individuals were living in the community, in nursing homes or were hospitalised, together with numbers studied, sex, mean age, criteria used to define anaemia, comorbidities and specific inclusion or exclusion criteria. For anaemia we sought details of overall prevalence, prevalence by age group, and prevalence in men and women separately. Where associations were found between anaemia and particular outcomes (mortality, cognitive function, disability) or medication use, these were also noted.

Two authors (HG, SD) carried out searching, study selection, and data extraction independently and disagreements were resolved by consensus (RAM, HG, SD).

It was recognised that the studies would be heterogeneous both in terms of the cohorts and the criteria used to define anaemia, so that any planned analysis should be simple and in large part qualitative. We did plan to calculate a weighted mean prevalence using the most commonly used definition of anaemia both overall, and for men and women separately. Sensitivity analyses were planned for community-living versus institutionalised (nursing home) or patients admitted to hospital, and for older (1980--1999) versus recent (2000--2006) studies. The weighted mean was calculated by dividing the sum of the product of prevalence (as percentage) and number of patients by the sum of the number of patients.

Results
=======

Electronic searches identified a total of 293 and 153 articles in Medline and EMBASE respectively, and many more from bibliographies of retrieved papers or \"linked articles\" in PubMed. A total of 83 studies were reviewed in detail, and 45 \[[@B9]-[@B53]\] were included, with details in Additional file [2](#S2){ref-type="supplementary-material"}. For two included studies \[[@B35],[@B40]\] the full paper was not available, but adequate details were given in the abstract, and another \[[@B25]\] was published as a letter rather than a full report. A list of excluded studies, with reason for exclusion, is in Additional file [3](#S3){ref-type="supplementary-material"}.

Most studies were of moderate size. The distribution of the 35 studies using WHO criteria of anaemia by size is shown in Table [1](#T1){ref-type="table"}. Only two examined at least 10,000 individuals (\[[@B13],[@B16]\] Table [1](#T1){ref-type="table"}), and the five studies with at least 5,000 individuals contributed over 60% of the total number of individuals. Twenty-six studies (76% of the total studies) examined fewer than 2,500 individuals (25% of total individuals). Almost half the 35 studies had fewer than 1,000 individuals, and contributed less than 8% of the total.

###### 

Studies reporting anaemia in older persons using WHO criteria

                   **Number of**   **Percent of total**          
  ---------------- --------------- ---------------------- ------ ------
  10,000--20,000   2               30,331                 5.9    35.5
  5,000--10,000    3               21,590                 8.8    25.3
  2,500--5,000     3               12,373                 8.8    14.5
  1,000--2,500     10              14,867                 29.4   17.4
  100--1,000       16              6,248                  47.1   7.3

The majority (34/45, 76%) of studies were of individuals living independently in the community, although a few included some individuals in nursing homes or hospital. Four studies \[[@B17],[@B22],[@B23],[@B40]\] were in nursing homes and seven studies \[[@B12],[@B14],[@B16],[@B25],[@B30],[@B37],[@B41]\] assessed patients who had been admitted to hospital.

The WHO criteria of Hb \< 130 g/L for men and \<120 g/L for women was by far the most commonly used to define anaemia, though we did accept results from three studies \[[@B15],[@B19],[@B43]\] that used thresholds within 5 g/L of these. Other criteria included Hb \< 140 g/L for men and 120 g/L for women, Hb levels of \<120 to \<80 g/L for both sexes, or various percentiles of the cohort. Haematocrit (Hct) levels are sometimes used to define anaemia. For example Hct 39% for men and 36% for women are alternative WHO criteria for defining anaemia \[[@B4]\], and two studies using Hct were included in the analysis of studies using WHO criteria (± 1%) \[[@B29],[@B52]\]. Where studies used a much lower concentration of haemoglobin to define anaemia, for instance \<120 g/L or \<110 g/L, we also extracted the prevalence information for these lower levels.

Thirty-four studies, with 85,409 individuals, using WHO criteria, yielded a weighted mean anaemia prevalence of 17% (range 3% to 50%). The weighted mean prevalence was 12% (3% to 26%) in 27 studies predominantly in the community (69,975 individuals), 47% (31% to 50%) in three studies in nursing homes (1481 individuals \[[@B17],[@B22],[@B53]\]) and 40% (40% to 72%) in four studies in hospital admissions (13,953 individuals \[[@B12],[@B14],[@B16],[@B25]\]; Table [2](#T2){ref-type="table"}). Figure [1](#F1){ref-type="fig"} shows the distribution of anaemia prevalence according to population (community, nursing home, and hospital admission) and cohort size. Anaemia was more prevalent in nursing homes or hospital admissions than in the community, and there was no overlap in anaemia prevalence between these groups (Figure [1](#F1){ref-type="fig"}).

###### 

Summary of results, including sensitivity analyses and use of alternative criteria for anaemia

  --------------------------------------- ----------------------- --------------------------- -------------------------------
                                          **Number of studies**   **Number of individuals**   **Anaemia (weighted mean %)**
                                                                                              
  **WHO criteria**                                                                            
                                                                                              
  All studies                             34                      85409                       17
  Community/Nursing Home                  31                      71456                       13
  Community only                          27                      69975                       12
  Nursing Homes only                      4                       1481                        47
  Hospital admissions only                3                       13953                       40
                                                                                              
  **Sensitivity analyses**                                                                    
                                                                                              
  Community/Nursing Home before 2000      12                      19708                       15
  Community/Nursing Home 2000 and later   18                      51748                       12
  Men                                     26                      23856                       15
  Women                                   28                      35781                       14
  Community only using Hb only            26                      68912                       12
                                                                                              
  **Alternative criteria**                                                                    
                                                                                              
  Community/Nursing Home Hb ≤ 120 g/L     3                       2516                        9
  Community/Nursing Home Hb ≤ 110 g/L     4                       21611                       6
  --------------------------------------- ----------------------- --------------------------- -------------------------------

Note: Individual studies were weighted by number of individuals for calculation of overall mean rate of anaemia
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Two studies in the community (2341 individuals) \[[@B39],[@B51]\], and one in a nursing home (175 individuals) \[[@B40]\] defined anaemia as Hb ≤ 120 g/L, giving prevalence rates of 7%, 11% (weighted mean 8%) and 24% respectively. A further three studies (21,170 individuals) \[[@B35],[@B51],[@B10]\] in the community and one in a nursing home (441 individuals) \[[@B17]\] used Hb ≤ 110 g/L, giving prevalence rates of 3%, 13%, 3% (weighted mean 6%) and 25% respectively. Generally, prevalence fell rapidly with lower thresholds, indicating that the vast majority of individuals classified as anaemic using WHO criteria were in fact only mildly anaemic.

Sensitivity analyses (Table [2](#T2){ref-type="table"}) examining the effect of publication date in the community or nursing home studies found similar prevalence in those published before 2000 (15%) and since 2000 (12%). Prevalence was slightly higher in men (15%) than women (14%) in studies reporting by sex. The two studies using Hct to define anaemia contributed less than 3% of the total population in community studies and excluding them did not alter the weighted mean estimate. Eight studies reported anaemia prevalence in different age groups, and there was a clear increase in prevalence with age (Figure [2](#F2){ref-type="fig"}). Other studies reported an increase in prevalence with age, but without giving the numbers.
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Five studies commented on prevalence of anaemia and ethnicity \[[@B52],[@B11],[@B21],[@B24],[@B42]\]. All indicated that anaemia prevalence was higher in black populations than white and Mexican-Americans, by a factor of about three times.

Discussion
==========

These results confirm that anaemia, as defined by the WHO criteria, is common in older people, affecting 1 in every 7 or 8 over-65s living in the community. Even using more stringent definitions of haemoglobin less than 120 g/L or 110 g/L, anaemia affects 1 in 12 to 1 in 15 older people in the community. In nursing homes, or in older people admitted to hospital, anaemia will be even more common, affecting almost 1 in 2. Higher prevalence occurs at greater age, and in black people.

These broad assertions have limitations. Firstly we have chosen to use the WHO criteria for defining anaemia because they are the most commonly reported. Threshold values are to some extent arbitrary, and WHO values are in the range of haemoglobin levels where the number of individuals captured changes rapidly. Choosing slightly different thresholds can considerably alter the number defined as anaemic. While we recognise the limitations of using thresholds, we have used WHO criteria because that is what is reported in the literature and because they do appear to be relevant, correlating with clinical outcomes.

We know, furthermore, that electronic searching for observational studies identifies fewer than half of studies, so that other methods have to be employed \[[@B7],[@B8]\]. While we examined bibliographies extensively, it is likely that some information was not identified by our searches. Though we limited our inclusion criteria to studies with at least 100 individuals, Table [1](#T1){ref-type="table"} demonstrates that small studies contributed little to the overall numbers, which were dominated by five studies of more than 5,000 individuals. Overall there was information on prevalence for almost 86,000 individuals, over 60% of whom were in these large studies. This justifies excluding prevalence studies with fewer than 100 subjects; non-inclusion of even 100 trials with fewer than 100 subjects would have contributed a maximum of 10% more to the total, and we found that 50% of the studies included with the smallest numbers actually contributed 8% to the total.

Only 34 of 45 studies used the WHO criteria of anaemia established in 1968 \[[@B4]\]. With highly variable definitions and prevalence clearly influenced by definition, we concentrated on the studies using the WHO definition. Additionally we arbitrarily imposed a 1980 cut off for publications to restrict influences from very different times from today. A sensitivity analysis comparing studies published between 1980 and 2000 and those after 2000 did not show any large temporal variation, though (Table [2](#T2){ref-type="table"}).

Even the studies we accessed did not all have the determination of anaemia prevalence in older people as their prime outcome. Rather, they were studies of association of anaemia with morbidity or disease, or examined anaemia as only one element of the study. Moreover, there were very limited amounts of information on important subgroups, like the oldest old, those with comorbities, or with ethnic or cultural differences. Information might be indicative, but it is difficult to have confidence in the precision of estimates in subgroups with such small numbers. More detailed studies can help, as with a recent study on racial variation and anaemia mortality and morbidity \[[@B54]\].

A degree of heterogeneity in the cohort studies was expected, and was found. We chose a crude separation between individuals living in the community, in nursing homes, or admitted to hospital as obvious differences between individuals, but within each cohort different distributions of age, ethnicity, and conditions would apply. Few studies tried, for instance, to give a population-based assessment by sampling according to a population norm. Sampling methods varied greatly. Some cohorts were inclusive, while others used random sampling, sometimes stratified, or with deliberate over-sampling of minority groups (ethnic, older old), and others did not specify methods.

Two very large studies could not be included because they did not define anaemia. The larger reported on over 1.1 million individuals in a general Medicare database \[[@B55]\], and reported patients with ICD-9-CM coding of anaemia rather than any particular threshold of haemoglobin or haematocrit. The diagnosis of anaemia was made in 15% of individuals, with a mean age of 77 years. Another large study of 43,510 nursing home residents reported 19% prevalence of anaemia, but without stating the criteria used \[[@B56]\]. Both were largely in line with the results of this review.

Another very large study of 91,000 patients with recent myocardial infarction could not be included because it used Hct of ≤ 39% as the threshold for anaemia in both men and women \[[@B57]\]. This study did give a breakdown by different haematocrit bands and sex, but reported a denominator from which individuals with high haematocrit values were excluded. Adding back these individuals, and assuming the same sex distribution amongst them as in the next highest band, gave an overall prevalence of 26% (28% in men, 25% in women). This is lower than the included studies of hospital admissions, but is difficult to interpret because of the clinical characteristics of the patients and the assumptions that had to be made to calculate prevalence.

A previous systematic review \[[@B58]\] included 71 studies on patients aged 60 years or older, but limited analysis to effects of sex differences reported in nine studies, and age differences reported in six studies. This new review used searches conduced about six years later, with wider inclusion criteria (such as abstracts), but more stringent criteria (such as definition of anaemia using WHO criteria, and exclusion of small studies). A consequence was that we reviewed a smaller number of studies, probably of higher quality, and examined issues not examined previously, such as the link between setting and anaemia prevalence.

The previous review concluded that anaemia prevalence was generally higher in men than women. We found only a small difference, but confined our comparison to studies using the same WHO criteria for anaemia, whereas Beghe et al \[[@B58]\] included studies using different definitions, including thresholds for men ranging from 110 g/L to 140 g/L. The finding of increasing prevalence with older age was confirmed in our analysis, though with more studies (Figure [2](#F2){ref-type="fig"}); we did not include one small report of anaemia prevalence of 53% in 89 centenarians \[[@B59]\]. This review, limited to persons aged 65 years and older, and to studies of at least 100 patients, additionally points to differences in anaemia prevalence between older people living in the community, in nursing homes, or admitted to hospital. The previous review \[[@B58]\] also noted the difficulties in drawing meaningful conclusions from disparate studies, and while we did extract potentially useful information from the studies (Additional file [2](#S2){ref-type="supplementary-material"}), we felt that clinical and methodological heterogeneity, and disparities in size, were too great to attempt further sensitivity analysis.

The rapid fall in prevalence of anaemia with definitions using lower thresholds (such as 110 g/L) suggests that in most cases the anaemia is mild. Despite this, the presence of anaemia in older people is associated with poorer outcomes. Older people (mean age 77 years) with anaemia suffered higher mortality (57%) than those without anaemia (39%) when followed up for almost 12 years \[[@B21]\]. Both anaemia and renal insufficiency appear to be independent risk factors for death among patients with heart failure \[[@B59]\] and after myocardial infarction \[[@B60]\], and anaemia predicts mortality in severe heart failure \[[@B61],[@B62]\]. Anaemia is also associated with increased risk of falls and impaired muscle strength \[[@B63]\], executive function impairment \[[@B64]\] and dementia \[[@B65]\], hospital admission \[[@B66]\], and longer hospital stay \[[@B50],[@B66]\].

Knowing the prevalence of anaemia in older people is important because we can begin to estimate the extent of the problem in this group. In the UK in 2007 there are almost 10 million people aged 65 years or older; the implication is that 1.5 million have anaemia as defined by WHO, and perhaps 600,000 have haemoglobin levels below 110 g/L. In thirty years there will probably be half as many again.

Studies have consistently demonstrated an approximately three times higher prevalence in black people between black and white people \[[@B5],[@B67]\] of all ages, not confined to the elderly, though differences narrowed when iron-deficient or thalassaemic patients were excluded \[[@B67]\]. While the reasons and consequences may be uncertain, and this is an area of some controversy, the use of different diagnostic criteria is not, so far, suggested, though attempts have been made to do so \[[@B5]\]. The literature we reviewed provided little information about the prevalence and consequences of the racial differences in anaemia. As has been pointed out \[[@B5]\], the genes of individuals classified as African-American could be anywhere between 10% and 90% of European origin. There is, in addition, a gradient in haemoglobin concentrations between whites of northern versus southern European ancestry \[[@B5]\]. This is clearly not a simple topic.

The similar prevalence found in studies published before and after 2000 suggests that significant advances in identifying and/or treating anaemia in older people have not been made in recent years. It is estimated that for between 14% and 50% of cases of anaemia in the elderly, the underlying cause is unexplained \[[@B24],[@B57]\]. We know little about whether it is preventable, or how much is associated with medications for other medical conditions of older age, except for NSAIDs \[[@B68]\] and perhaps low dose aspirin \[[@B13]\]. There does not appear to be an extensive literature on therapy, and whether therapy improves quality of life and outcomes in older people.

We, as others before \[[@B58]\], find the limitations of the literature, especially the small number of larger studies in defined communities with defined criteria, limit any methodological considerations without the danger of over analysis. To some extent the unanswered questions are more interesting than those that can be answered -- for example about the causes, health and economic consequences, and treatment of anaemia in older people, and the desirability or otherwise of using different action levels than the WHO definitions of anaemia. While the usual call for more research is often rather lame, in this case the extraordinary expected growth in the numbers of older people, coupled with the high prevalence and potentially serious consequences of anaemia, suggest that in this case more research is a sensible conclusion.

Conclusion
==========

Anaemia as defined using WHO criteria is common in older people living in the community, and is higher in the older old and black people. It is particularly common amongst nursing home residents and older people admitted to hospital. The presence of anaemia is associated with a worse prognosis, with increases in morbidity and mortality. Predicted demographic changes will increase the burden and underline the need to understand more about anaemia in older people.

Abbreviations
=============

WHO World Health Organisation

Hb haemoglobin

Hct haematocrit

NSAID non-steroidal anti-inflammatory drug
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